The company has launched its Silodosin capsules in the strengths of 4 mg and 8 mg after receiving an approval from the United States Food and Drug Administration (USFDA) earlier, the company said in a statement.
The company's product is generic equivalent of Allergan's Rapaflo capsules, it added.
As per IQVIA MAT September 2018 data, Rapaflo had annual sales of USD 198.5 million in the US, Lupin said.
Shares of Lupin today closed at Rs 888.05 per scrip on BSE, down 1.14 per cent from its previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)